Nautilus Biotechnology Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table presents fees for professional audit services and other services rendered by PricewaterhouseCoopers LLP to us for our fiscal years ended December 31, 2023 and 2022.
| 2023 | 2022 | |
|---|---|---|
| Audit Fees(1) | $913,000 | $863,500 |
| Audit-Related Fees | — | — |
| Tax Fees | — | — |
| All Other Fees(2) | 2,900 | 3,078 |
| Total Fees | $915,900 | $866,578 |
| (1) | “Audit Fees” consist of fees billed for professional services rendered in connection with the audit of our financial statements, reviews of our quarterly financial statements and related accounting consultations and services that are normally provided by the independent registered public accountants in connection with statutory and regulatory filings or engagements for those fiscal years. |
| (2) | “All Other Fees” consist of the cost of a subscription accounting research software. |
Auditor Independence
In 2023, there were no other professional services provided by PricewaterhouseCoopers LLP, other than those listed above, that would have required our audit committee to consider their compatibility with maintaining the independence of PricewaterhouseCoopers LLP.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.